Top Markets
Coin of the day
Mustang Bio, Inc. Mustang Bio, Inc.

Mustang Bio, Inc.

MBIO
Rang in Aktien #35075
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Aktienkurs
$0.594
Zuletzt synchronisiert: 2026-08-14
Marktkapitalisierung
$4.50M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-66.44%
Land
US
Handel Mustang Bio, Inc. (MBIO)

Kategorie

Aktien-Split-Historie für Mustang Bio, Inc. (MBIO)
Die Aktie Mustang Bio, Inc. (Symbol: MBIO) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 16, 2026 statt.
Eine MBIO-Aktie, die vor dem Aug 16, 2026 gekauft wurde, entspricht heute 0 MBIO-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE